• 1
    Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 2003; 124: 248250.
  • 2
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 14131419.
  • 3
    Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 11031109.
  • 4
    Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. HEPATOLOGY 1995; 22: 17141719.
  • 5
    McCullough AJ. The epidemiology and risk factors of NASH. In: Farrell GC, George J, Hall P, et al., eds. Fatty Liver Disease: NASH and Related Disorders. Oxford, UK: Blackwell; 2005: 2337.
  • 6
    Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. HEPATOLOGY 2009; 49: 306317.
  • 7
    Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 2006; 40: 3438.
  • 8
    Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745750.
  • 9
    Chave G, Milot T, Pilleul F. Out of phase magnetic resonance imaging and liver applications. J Radiol 2005; 86: 993997.
  • 10
    Suzuki A, Angulo P, Lymph J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005; 25: 779786.
  • 11
    Degertegin B, Ozenirler S, Elberg S, Akyol G. Serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis. Dig Dis Sci 2007; 52: 26222628.
  • 12
    Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that accurately identifies liver fibrosis in patients with NAFLD. HEPATOLOGY 2007; 45: 846853.
  • 13
    Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. HEPATOLOGY 2008; 47: 455460.
  • 14
    Wang M, You J, Bemis KG, Tegeler TJ, Brown DP. Label-free mass spectrometry-based protein quantification technologies in proteomic analysis. Brief Funct Genomic Proteomics 2008; 7: 329339.
  • 15
    Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. HEPATOLOGY 2003; 37: 544550.
  • 16
    Chalasani N, Deeg MA, Persohn S, Crabb DW. Metabolic and anthropometric evaluation of insulin resistance in non-diabetic patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 18491855.
  • 17
    Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 14971502.
  • 18
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248254.
  • 19
    Hale JE, Butler JP, Gelfanova V, You JS, Knierman MD. A simplified procedure for the reduction and alkylation of cysteine residues in proteins prior to proteolytic digestion and mass spectral analysis. Anal Biochem 2004; 333: 174181.
  • 20
    Higgs RE, Knierman MD, Gelfanova V, Butler JP, Hale JE. Comprehensive label-free method for the relative quantification of proteins from biological samples. J Proteome Res 2005; 4: 14421450.
  • 21
    Craig R, Beavis RC. TANDEM: matching proteins with tandem mass spectra. Bioinformatics 2004; 20: 14661467.
  • 22
    Eng J, McCormack A, Yates RR. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 1994; 5: 976989.
  • 23
    Higgs RE, Knierman MD, Freeman AB, Gelbert LM, Patil ST, Hale JE. Estimating the statistical significance of peptide identifications from shotgun proteomics experiments. J Proteome Res 2007; 6: 17581767.
  • 24
    Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185193.
  • 25
    Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. HEPATOLOGY 2005; 42: 665674.
  • 26
    Charlton M, Viker K, Krishnan A, Sanderson S, Veldt B, Kaalsbeek AJ, et al. Differential expression of lumican and fatty acid binding protein-1 — new insights into the histologic spectrum of non-alcoholic fatty liver disease. HEPATOLOGY 2009; 49: 13751384.
  • 27
    Yan W, Chen SS. Mass spectrometry-based quantitative proteomic profiling. Brief Funct Genomic Proteomics 2005; 4: 2738.
  • 28
    Zhang B, VerBerkmoes NC, Langston MA, Uberbacher E, Hettich RL, Samatoma NF. Detecting differential and correlated protein expression in label-free shotgun proteomics. J Proteome Res 2006; 5: 29092918.
  • 29
    Wang G, Wu WW, Zeng W, Chou CL, Shen RF. Label-free protein quantification using LC-coupled ion trap or FT mass spectrometry: reproducibility, linearity, and application with complex proteomes. J Proteome Res 2006; 5: 12141223.
  • 30
    Ono M, Shitashige M, Honda K, Isobe T, Kuwabara H, Matsuzuki H, et al. Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol Cell Proteomics 2006; 5: 13381347.
  • 31
    Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356362.
  • 32
    Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 25522263.
  • 33
    Janke J, Engeli S, Boschmann M, Adams F, Böhnke J, Luft FC, et al. Retinol-binding protein 4 in human obesity. Diabetes 2006; 55: 28052810.
  • 34
    Seo JA, Kim NH, Park SY, Kim HY, Ryu OH, Lee KW, et al. Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease. Clin Endocrinol 2007; 68: 555560.
  • 35
    Nobili V, Alkhouri N, Alisi A, Ottino S, Lopez R, Manco M, et al. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 575579.
  • 36
    Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis. Turk J Gastroenterol 2003; 14: 1217.
  • 37
    Mas VR, Maluf DG, Archer KJ, Yanek K, Bornstein K, Fisher RA. Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation 2009; 87: 143152.
  • 38
    Chaerkady R, Harsha HC, Nalli A, Gucek M, Vivekanandan P, Akhtar J, et al. A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma. J Proteome Res 2008; 7: 42894298.
  • 39
    Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig Liver Dis 2004; 36: 231242.
  • 40
    Bell AW. Lipid metabolism in liver and selected tissues and in the whole body of ruminant animals. Prog Lipid Res 1979; 18: 117164.
  • 41
    Tietge UJ, Boker KH, Bahr MJ, Weinberg S, Pichlmayr R, Schmidt HH, et al. Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation. Hepatogastroenterology 1998; 45: 22552260.
  • 42
    Sherlock S. Alcoholic liver disease. Lancet 1995; 345: 227229.
  • 43
    Gobel T, Vorderwulbecke S, Hauck K, Fey H, Haussinger D, Erhardt A. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol 2006; 12: 76047612.
  • 44
    Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009; 46: 83106.
  • 45
    Choudhury J, Sanyal AJ. Clinical aspects of fatty liver disease. Semin Liver Dis 2004; 24: 349362.